Medrack.Health Oral cancer medicine guide Commonly prescribed forEGFR-mutation-positive non-small-cell lung cancer (first-line and T790M-resistant)
This page explains the medicine in plain language and how a prescription-led access request is assessed for a patient in Ghana. Treatment decisions always stay with the treating oncology team.
We do not display prices publicly. If a request is eligible, the available medicine details, documentation and any further arrangements are confirmed in writing for that individual case.
Osimertinib is the active ingredient in Tagrisso, used for egfr-mutation-positive non-small-cell lung cancer (3rd-gen tki). It is supplied as a tablet in strengths of 40 mg, 80 mg, manufactured by the originator. This is the originator brand Tagrisso (AstraZeneca, India) itself, sourced on the Indian market - not a generic substitute.
Innovator brand available in India This is the originator brand Tagrisso (AstraZeneca, India) itself, sourced on the Indian market. There is no Indian generic of this medicine.
| Sold in India as | Manufacturer |
|---|---|
| Tagrisso | AstraZeneca India |
Do not make a treatment or payment decision from a public product page. Discuss treatment with the patient's clinician and wait for written case information.
Osimertinib is a third-generation EGFR tyrosine-kinase inhibitor. It selectively blocks mutated EGFR signalling (including the T790M resistance mutation) that drives certain lung cancers, and crosses into the brain to treat CNS spread.
Usual dose is 80 mg once daily, with or without food, as directed by the treating oncologist. Taken continuously while it remains effective.
Available strengths: 40 mg, 80 mg. Always follow your own doctor's instructions.
Common or notable side effects include:
This is not a complete list. Read the patient leaflet and seek medical advice for anything severe or unexpected.
Specialist oncology supervision is essential. Regular monitoring (heart, lungs, bloods) is required. Many interactions - share your full medication list. Supplied only against a valid specialist prescription through our assisted process.
This is not a generic. Tagrisso is Osimertinib, made by the originator, and what we supply is that same originator product sourced on the Indian market - the identical product, from the identical manufacturer, in sealed original packaging. There is no bioequivalence question to ask because there is no substitution: the medicine is the originator's own. For any eligible case, the proposed product and available documentation are confirmed in writing before a patient or caregiver makes a further decision.
Tagrisso is still under patent in India, so no Indian generic exists and none is sold here. Whether an appropriate access route can be considered for Ghana depends on the prescription, current availability, documentation and destination requirements. Medrack.Health confirms only the details applicable to an individual eligible case.
A son, daughter, spouse or another caregiver may start a request on behalf of the patient, including from another country. Enter the patient's name exactly as it appears on the prescription. The prescription should come from the patient’s treating clinician; we then assess whether an appropriate route may be available for Ghana.
Submit a request with the medicine, strength, patient details and destination. We assess the prescription status and whether an appropriate route may be available. If a case is eligible, the proposed medicine details, documentation, total cost and delivery options are confirmed in writing before you decide whether to proceed.
Medrack.Health is currently focused on Ghana and Kenya. It does not guarantee availability, import approval, customs clearance, delivery timing or supply from a public product page.
This medicine uses our assisted process: your request and prescription status are assessed before any possible next step is discussed.
Oncology medicines require a valid prescription, pharmacist review, batch verification and destination-country checks. Our assisted process handles all of this - typically within 2-3 business days.
It is real Tagrisso, made by AstraZeneca. Osimertinib is still under patent in India, so no Indian generic exists - what we supply is the originator pack sourced on the Indian market, in sealed original packaging. We share the batch number so you can verify it.
This page is general information, not medical advice. Always consult your own doctor about whether Osimertinib is right for you.
Help us improve this guide. Please do not include prescription, diagnosis or other personal health information.